Skip to navigation Skip to content

Commercial Research Funding


Commercial R&D Funding

Through Fast Forward, we are making high-impact early-stage investments to accelerate commercial Research and Development for new therapies, diagnostics, and symptom management strategies for MS.

As a driving force of MS research to find pathways to a cure, the National MS Society takes a unique, comprehensive approach to funding research efforts. Since 2008 the National MS Society, through Fast Forward, has been driving the development of new therapies and diagnostics for people living with MS. Fast Forward  bridges the preclinical commercial funding gap, targets funds to de-risk therapeutic development and catalyzes further commercial investment.

Learn more about Fast Forward

Therapeutic Development Opportunities for Symptom Management in Multiple Sclerosis
The purpose of this request for proposals (RFP) is to fund commercial development opportunities for symptom management in MS. Such symptoms include motor impairment (problems with mobility, balance, coordination or upper extremity dysfunction), fatigue, pain, cognitive impairment, mood (emotional changes, depression), spasticity and bowel or bladder dysfunction.
Both pharmacologic and non-pharmacologic interventions with commercial viability will be considered.

Details on the current funding opportunity are available to download below. To submit a proposal for Fast Forward support, applicants must first register with our online portal ( and complete a brief pre-application. Staff will review the pre-application to determine whether the proposed research plan is appropriate and relevant to the objectives of the Request for Proposals (RFP).

Important dates:
Pre-applications will be accepted beginning November 12, 2019
Final date for acceptance of pre-applications: January 8, 2020
Final date for receipt of completed full applications: January 15, 2020 

Additional information: For more information, please contact:

Mark Allegretta PhD    
Vice President, Research
Maya Merrell
Director, Business and Partnership Development
Walter Kostich PhD    
Director, Commercial Research


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.